Comparing preemptive injection of peri-articular-multimodal drug with oral celexocib for postoperative pain management in total knee arthroplasty: A randomized clinical trial.

BACKGROUND

Total knee arthroplasty (TKA) is associated with tremendous postoperative pain, and pain relief should concisely be considered. This study aims to compare the efficacy of preemptive periarticular multimodal drug injection versus placebo and oral celecoxib on postoperative pain control after TKA.

MATERIALS AND METHODS

This study is a randomized clinical trial on 146 patients candidate for TKA who were randomly allocated to three treatment groups, including (1) a cocktail consisting of bupivacaine, morphine, epinephrine, and ketorolac ( = 48), (2) only epinephrine (placebo group) ( = 49), and (3) 400 mg celecoxib orally (control group) ( = 49) using the Random Allocation software. The injections and oral therapy were performed within 15 min before the surgical procedure. The study's primary outcome was the Knee Society Score (KSS) calculated at baseline, within 6 weeks and 6 months postoperatively. Range of motion (ROM) and Visual Analog Scale (VAS) to assess pain intensity as the other primary outcomes were evaluated before the procedure, within 24 h, 48 h, and 6 weeks postoperatively.

RESULTS

The three studied groups were similar regarding demographic characteristics, including age ( = 0.33), gender distribution ( = 0.65), and involved knee side ( = 0.94). Baseline comparison of KSS ( = 0.39), VAS ( = 0.24), and ROM ( = 0.37) among the groups revealed insignificant differences. All the studied groups showed a statistically significant trend of improvement in KSS, VAS, and ROM ( < 0.001), while the comparison of the three groups in terms of KSS ( = 0.001), VAS ( < 0.001), and ROM ( < 0.001) revealed remarkable superiority of multimodal injection to the other treatments.

CONCLUSION

Preemptive periarticular multimodal drug injection, including bupivacaine, morphine, epinephrine, and ketorolac, can cause considerable postoperative pain relief and better ROM achievement in comparison to placebo or oral celecoxib.